Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease.

Penkert RR, Young NS, Surman SL, Sealy RE, Rosch J, Dormitzer PR, Settembre EC, Chandramouli S, Wong S, Hankins JS, Hurwitz JL.

Vaccine. 2017 Jun 22;35(29):3615-3620. doi: 10.1016/j.vaccine.2017.05.022. Epub 2017 May 26.

PMID:
28554503
2.

Human Parvoviruses.

Qiu J, Söderlund-Venermo M, Young NS.

Clin Microbiol Rev. 2017 Jan;30(1):43-113. Review.

PMID:
27806994
3.

The effects of co-infection with human parvovirus B19 and Plasmodium falciparum on type and degree of anaemia in Ghanaian children.

Duedu KO, Sagoe KW, Ayeh-Kumi PF, Affrim RB, Adiku T.

Asian Pac J Trop Biomed. 2013 Feb;3(2):129-39. doi: 10.1016/S2221-1691(13)60037-4.

4.
5.

Safety and immunogenicity of a candidate parvovirus B19 vaccine.

Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, Wong S, Shelly D, Young NS, Dempsey W.

Vaccine. 2011 Oct 6;29(43):7357-63. doi: 10.1016/j.vaccine.2011.07.080. Epub 2011 Jul 30.

6.

Parvovirus B19 - Revised.

Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Montag-Lessing T, Offergeld R, Pauli G, Seitz R, Schlenkrich U, Schottstedt V, Strobel J, Willkommen H, von König CH.

Transfus Med Hemother. 2010;37(6):339-350. Epub 2010 Nov 17. No abstract available.

7.

Parvovirus B19 infection in human pregnancy.

Lamont RF, Sobel JD, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, Uldbjerg N, Romero R.

BJOG. 2011 Jan;118(2):175-86. doi: 10.1111/j.1471-0528.2010.02749.x. Epub 2010 Oct 13. Review.

8.

Block copolymer micelles as nanocontainers for controlled release of proteins from biocompatible oil phases.

Miller AC, Bershteyn A, Tan W, Hammond PT, Cohen RE, Irvine DJ.

Biomacromolecules. 2009 Apr 13;10(4):732-41. doi: 10.1021/bm800913r.

9.

[Viral infections of the fetus and newborn infant].

Tremolada S, Delbue S, Ferrante P.

Pediatr Med Chir. 2008 Jul-Aug;30(4):177-91. Review. Italian.

10.

High rate of severe fetal outcomes associated with maternal parvovirus b19 infection in pregnancy.

Beigi RH, Wiesenfeld HC, Landers DV, Simhan HN.

Infect Dis Obstet Gynecol. 2008;2008:524601. doi: 10.1155/2008/524601.

11.

Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection.

Mossong J, Hens N, Friederichs V, Davidkin I, Broman M, Litwinska B, Siennicka J, Trzcinska A, VAN Damme P, Beutels P, Vyse A, Shkedy Z, Aerts M, Massari M, Gabutti G.

Epidemiol Infect. 2008 Aug;136(8):1059-68. Epub 2007 Oct 24.

12.

Pure red cell aplasia due to parvovirus B19 infection after liver transplantation: a case report and review of the literature.

Liang TB, Li DL, Yu J, Bai XL, Liang L, Xu SG, Wang WL, Shen Y, Zhang M, Zheng SS.

World J Gastroenterol. 2007 Apr 7;13(13):2007-10. Review.

13.

T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Franssila R, Auramo J, Modrow S, Möbs M, Oker-Blom C, Käpylä P, Söderlund-Venermo M, Hedman K.

Clin Exp Immunol. 2005 Oct;142(1):53-61.

14.

Hereditary spherocytosis; new guidelines.

Bolton-Maggs PH.

Arch Dis Child. 2004 Sep;89(9):809-12. No abstract available.

Supplemental Content

Support Center